GLEN
ALLEN, Va., May 7, 2024
/PRNewswire/ -- Remidio Inc., a health technology innovator
developing cutting-edge technology to combat global blindness from
Diabetic Retinopathy, Glaucoma, AMD, & Cataracts, is all set to
achieve a significant milestone.
This quarter, Remidio Inc. is excited to be placing its
1000th FOP-NM handheld fundus camera in the hands of US
healthcare providers. Since 2019, these devices have been
supporting diabetic retinopathy screening activities of over 3,500
high volume healthcare providers in the US.
Remidio's FOP-NM is the world's first smartphone-based
non-mydriatic fundus camera, eliminating the need for patient
dilation and is rapidly revolutionizing retinal examinations in the
US; both within clinic settings and beyond, with equal impact.
The FOP-NM is an easy to use, easy to train retinal camera that
provides excellent image quality empowering medical specialists and
non-specialists (nurses, or any healthcare personnel) to conduct
retinal exams anywhere: in the clinic, home, in emergency rooms or
remote rural healthcare centres.
The portability of the device has also found widespread
acceptance from university health systems as well, such as the
University of Virginia, and several
others.
University of Virginia's Assistant
Professor of Ophthalmology, Dr. Arjun
Dirghangi has this to add, "Remidio's FOP-NM is easier to
use, easy to train on. We have gotten good images, even from
trainees who have never used the system before, within 30 seconds
to 2 minutes per eye. My goal at the end of the day is to improve
access to screening. And this is certainly one of the more powerful
tools that I have seen to be able to do that."
While numerous handheld retinal cameras tout 'excellent image
quality', Remidio's FOP-NM stands out. In a comparative, clinical
validation study published in Nature Eye, Remidio's FOP-NM offered
image quality at par to the "gold standard of imaging"
The clinically validated technology of the FOP-NM, along with
its ease-of-use, ushers in workflows for screening retinal
conditions where image acquisition is effortless even for a novice
user.
Remidio's Chief Commercial Officer, Erik
Hafkey, further adds, "Our goal is to impact the lives of
nearly 30M at risk for Diabetic
Retinopathy in the US. New partnerships with proven technologies
will be required to reach this goal. Remidio is delighted to open
our hardware and telehealth platform for collaboration with AI SaMD
companies and care providers working to bring care closer to the
patient. As our vision for using retinal imaging, viewing the
"windows to our body", won't end with just eye diseases. We
seek out many other chronic conditions that may be caught early
using retinal imaging. The portability, affordability, and ease of
use of Remidio devices naturally fit into already existing clinical
workflows, enabling this technology to quickly scale its
impact."
As Remidio continues to break new ground with their technology
and collaborations, the team of 170+ at Remidio remains dedicated
to a single vision: building a healthier tomorrow in a world where
advanced technology and its users come together to ensure eye
health for all, making a difference in the lives of millions, one
vision at a time.
Remidio is an innovative ISO 13485-certified medical device
company that seeks to impact preventable blindness by creating
accessible technologies that are smart and simple to use. Remidio's
CE marked, and FDA 510k registered
medical devices have helped screen and impact more than 15 million
patients in 40+ countries globally.
Media Contact: Erik Hafkey
Chief Commercial Officer
erik@remidio.com
+1 - 888-627-1416
Photo:
https://mma.prnewswire.com/media/2405447/Remidio_s_FOP_NM.jpg
Logo:
https://mma.prnewswire.com/media/2405840/Remidio_Innovative_Solutions_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/health-tech-innovator-remidio-achieves-unprecedented-scale-in-the-us-with-its-revolutionary-retinal-solutions-302137533.html
SOURCE Remidio Innovative Solutions